In vitro activity of imipenem/releactam and comparator agents against clinical bacterial isolates from patients with cancer

•Imipenem/Relebactam is active against 98% of Enterobacteriales from cancer patients•Imipenem/Relebactam had potent activity against ESBL producing E. coli and K. pneumoniae•Potent activity against achromobacter spp. And non-MDR p. aeruginosa•Inhibited 87% of non-enterobacterales isolates excluding s. maltophilia•Moderate activity against MDR p. aeruginosa